

## MATERIAL CHANGE REPORT

### PURSUANT TO SECTION 7.1 OF NATIONAL INSTRUMENT 51-102 RESPECTING CONTINUOUS DISCLOSURE OBLIGATIONS

ITEM 1: **Name and Address of Corporation**

Terranueva Corporation (« **Terranueva** » or the « **Corporation** »)  
255, Curé-Labelle Blvd., suite 204  
Laval, Québec  
H7L 2Z9

ITEM 2: **Date of Material Changes**

April 12, 2019.

ITEM 3: **News Release**

A press release was issued in English and French by Terranueva on April 15, 2019. Copies of each version are attached hereto.

ITEM 4: **Summary of Material Changes**

Terranueva secures option for 280,000 sq. ft. to continue expansion plans at L'Assomption

ITEM 5: **Full Description of Material Changes**

Terranueva announces that, following the issuance of culture, transformation and sale (medical) licenses issued by Health Canada on February 22, the Corporation pursued its development plan by securing contingent options to purchase over 280,000 square feet of land adjacent to its state-of-the-art plant located in L'Assomption, Quebec. This means that the Corporation now has more than 410,000 sq. ft. of land to expand its activities.

Thanks to these options, Terranueva will be able to optimize its future production and provide it with attractive operational synergies. The Corporation estimates that, in the long term and subject to the exercise of these options, it can add approximately 32 metric tons of medical and recreational cannabis per year to its total production.

Terranueva recently started cannabis production at its plant in L'Assomption, Quebec. In addition, as announced on February 25, Terranueva is well on its way to completing Phase 2 of its business plan to design and build the first modular production units on its 130,000 sq. ft. lot. The start of construction of the first two modular production units is planned for this summer.

"Now that we have started the culture of a hybrid strain to our full satisfaction and have completed our tender for the construction of our first modular units, it was time to optimize the land area that will allow us to take full advantage of expansion required for our activities over the next few years." said Pierre Ayotte, CEO of Terranueva.

Terranueva plans to generate revenue in 2019. The Corporation's business plan aims to multiply these revenues quickly by adding modular production units over the next three years.

ITEM 6: **Reliance on Subsection 7.1(2) or (3) of National Instrument 51-102**

Not applicable.

ITEM 7: **Omitted Information**

Not applicable.

ITEM 8 **Executive Officer**

For further information, please contact Mr. Pierre Monet, Chief Financial Officer, at (514) 883-8733.

ITEM 9: **Date of Report**

April 18, 2019.



# TERRANUEVA

COMMUNIQUÉ DE PRESSE

POUR DIFFUSION IMMÉDIATE

SYMBOLE BOURSIER : TEQ

LE 15 AVRIL 2019

## **Terranueva sécurise une option pour 280 000 pi<sup>2</sup> afin de poursuivre ses plans d'expansion à L'Assomption**

Montréal, QC – Corporation Terranueva (CSE: TEQ) (« Terranueva » ou la « Société ») est heureuse d'annoncer qu'à la suite de l'octroi des licences de culture, transformation et vente (médical) émises par Santé Canada le 22 février dernier, la Société a poursuivi son plan de développement en sécurisant des options d'achat contingentes sur une superficie de plus de 280 000 pi<sup>2</sup> contigus à son usine à la fine pointe de la technologie située à L'Assomption au Québec (les « Options »). C'est donc dire que la Société dispose de plus de 410 000 pi<sup>2</sup> dans le cadre de ses activités.

Grâce à ces Options, Terranueva sera en mesure d'optimiser sa production future et de lui procurer d'intéressantes synergies opérationnelles. La Société estime qu'à terme et sous réserve de l'exercice des Options, elle pourra ajouter environ 32 tonnes métrique de cannabis médical et récréatif par an à sa production totale.

Par ailleurs, Terranueva a amorcé la production de cannabis à son usine de L'Assomption au Québec. De plus, tel qu'annoncé le 25 février dernier, Terranueva est bien engagé dans la réalisation de la phase 2 de son plan d'affaires qui consiste à concevoir et construire les premières unités de production modulaires sur son terrain de 130 000 pi<sup>2</sup>. Le début de la construction des deux premières unités de production modulaires est prévu pour cet été.

« Maintenant que nous avons amorcé la culture de souche hybride à notre entière satisfaction et que nous avons conclu notre appel d'offre pour la construction de nos premières unités modulaires, il était temps d'optimiser la superficie foncière qui nous permettra de prendre toute l'expansion nécessaires à nos activités au cours des prochaines années. » a déclaré Pierre Ayotte, Chef de la direction de Terranueva.

Terranueva prévoit générer des revenus au cours de l'année 2019. Le plan de développement de l'entreprise vise à multiplier ces revenus rapidement en ajoutant des unités de production modulaire au cours des trois prochaines années.

## **A PROPOS DE TERRANUEVA**

Terranueva s'appuie sur la recherche et développement et l'efficacité opérationnelle pour devenir un acteur incontournable dans l'industrie émergente du cannabis. Nous visons à fournir aux marchés canadien et international du cannabis médical et récréatif de première qualité.

Corporation Terranueva Pharma, sa filiale détenue en propriété exclusive détient les licences nécessaires de Santé Canada pour exécuter sa mission. Opérant à l'Assomption (Québec), sa mission est de produire du cannabis aux normes les plus élevées en termes d'efficacité, de qualité et de stabilité. Pour atteindre son objectif, Terranueva Pharma met en œuvre une approche de production modulaire intégrant les dernières avancées et innovations dans l'automatisation de ces processus.

Pour en savoir plus sur Terranueva, consulter [www.terranevea.ca](http://www.terranevea.ca).

*La CSE, et ses fournisseurs de services de réglementation (au sens attribué à ce terme dans ses politiques) n'assument aucune responsabilité quant à la pertinence ou à l'exactitude du présent communiqué.*

### **Pour plus d'information, veuillez contacter :**

Corporation Terranueva:

Pierre Monet, Chef de la direction financière

Téléphone : (514) 883-8733

[pmonet@terranevea.ca](mailto:pmonet@terranevea.ca)



# TERRANUEVA

PRESS RELEASE

**FOR IMMEDIATE RELEASE**

**STOCK SYMBOL: TEQ**

**APRIL 15, 2019**

## **Terranueva secures option for 280,000 sq. ft. to continue expansion plans at L'Assomption**

Montréal, QC - Terranueva Corporation (CSE: TEQ) ("Terranueva" or the "Corporation") is pleased to announce that, following the issuance of culture, transformation and sale (medical) licenses issued by Health Canada on February 22, the Company pursued its development plan by securing contingent options to purchase over 280,000 square feet of land adjacent to its state-of-the-art plant located in L'Assomption, Quebec (the 'Options'). This means that the Company now has more than 410,000 sq. ft. of land to expand its activities.

Thanks to these Options, Terranueva will be able to optimize its future production and provide it with attractive operational synergies. The Company estimates that, in the long term and subject to the exercise of these Options, it can add approximately 32 metric tons of medical and recreational cannabis per year to its total production.

Terranueva recently started cannabis production at its plant in L'Assomption, Quebec. In addition, as announced on February 25, Terranueva is well on its way to completing Phase 2 of its business plan to design and build the first modular production units on its 130,000 sq. ft. lot. The start of construction of the first two modular production units is planned for this summer.

"Now that we have started the culture of a hybrid strain to our full satisfaction and have completed our tender for the construction of our first modular units, it was time to optimize the land area that will allow us to take full advantage of expansion required for our activities over the next few years. " said Pierre Ayotte, CEO of Terranueva.

Terranueva plans to generate revenue in 2019. The company's business plan aims to multiply these revenues quickly by adding modular production units over the next three years.

**About Terranueva :**

Terranueva relies on research and development and operational efficiency to become a key player in the emerging cannabis industry. It aims to provide the Canadian and international markets with first-rate medicinal and recreational cannabis.

Terranueva Pharma Corporation, its wholly owned subsidiary, holds the necessary licenses from Health Canada to meet its mission. Operating in L'Assomption (Quebec), its mission is to produce cannabis with the highest standards in terms of efficiency, quality and stability. To achieve its goal, Terranueva Pharma is implementing a modular production approach, integrating the latest advances and innovations in process automation.

Learn more about Terranueva at [www.terranevea.ca](http://www.terranevea.ca)

*CSE nor its services providers (as that terms defined in the policies) accept responsibility for the adequacy or accuracy of this press release.*

**For further information, please contact:**

Terranueva Corporation:

Pierre Monet, Chief financial officer

Téléphone : (514) 883-8733

[pmonet@terranevea.ca](mailto:pmonet@terranevea.ca)